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Abstract 
 
Cognitive behavior therapy (CBT) is the psychological treatment of choice for panic 
disorder (PD). But given limited access to CBT it must be delivered with maximal 
cost-effectiveness.  Previous research has found that a brief computer-augmented 
CBT was as effective as extended therapist-delivered CBT.  In order to test this 
finding 163 patients with PD across two sites in Scotland and Australia were 
randomly allocated to12 sessions of therapist delivered CBT (CBT12), 6 sessions of 
therapy either therapist-delivered (CBT6) or with computer augmentation (CBT6-
CA), or a wait list control.  At post treatment CBT12 was more effective than CBT6 
but not different from CBT6CA, however CBT6 did not differ from CBT6CA. The 
active treatments did not differ statistically at 6-month follow up. The study provided 
some support for the use of computers as an innovative adjunctive therapy tool and 
merits further investigation. 
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A Comparison of Delivery Methods of Cognitive-Behavioral Therapy for Panic 
Disorder:  An International Multi-center Trial. 
Substantial research evidence indicates that the psychological treatment of 
choice for panic disorder is cognitive-behavioral intervention (CBT) (Barlow, 
Gorman, Shear & Woods, 2000; Hofmann & Spiegel, 1999; Otto, Pollack & Maki, 
2000.) As a result there has been a corresponding growth of demand for treatment, an 
increase in waiting times in some health care systems and, consequently, pressure for 
more accessible and efficient forms of treatment delivery. 
This need is further highlighted by the high prevalence of panic disorder 
(Kessler, McGonagle, Zhao, Nelson, Hughes, Eshleman, et al, 1994), as well as the 
nature of the condition that often involves a level of agoraphobic avoidance. This may 
limit regular clinic attendance and access to conventional therapist-administered 
treatment (Côté, Gauthier, Laberge, Cormier & Plamondon, 1994).  To date, one of 
the main alternatives to conventional CBT delivery has involved the use of written 
self-help materials or bibliotherapy. 
Bibliotherapy (Dow, 1982) has proven to be as effective as eight sessions of 
group or individual CBT (Lidren, Watkins, Gould, Clum, Asterino, & Tulloch, 1994) 
although Power, Sharp, Swanson, and Simpson (2000) found a totally self-
administered bibliotherapy condition to be significantly less effective on a range of 
outcome measures compared to ‘standard’ therapist delivered CBT.   This may be 
related to inaccessibility and inconvenience of bibliotherapy during daily activities. 
One possible solution to the limits of bibliotherapy lies in computer-assisted therapy. 
Computers can increase patient access to treatment programs (Kenardy, McCafferty & Rosa, 
2003), extend therapy to the patient’s own environment and enhance cost-effectiveness with 
costs reduced to between one-third and one-sixth of conventional behavioral treatment 
(Kenardy & Adams, 1993, Newman, 2000.) Computer programs have been shown to be 
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effective adjuncts to more conventional treatment for a variety of anxiety disorders, 
including panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, 
and generalized anxiety disorder (Newman, 2000). With the advent of powerful, 
inexpensive hand-held computers, it has become possible to provide a realistic version 
of CBT that may be used in the patient’s own environment 
Preliminary studies by Kenardy, Fried, Taylor, and Kraemer (1992) on the use 
of hand held computers to aid monitoring of anxiety and coping ability among panic 
disorder patients showed that the computers were well accepted, led to increased 
compliance and more reliable self-monitoring.  In a further pilot study, Newman, 
Kenardy, Herman and Taylor (1997) randomly assigned 18 patients to a standard (12-
session) CBT condition based on Panic Control Treatment, or a brief (4 session) 
computer-assisted CBT condition.  The results showed that both treatments were 
equally effective at post treatment and at six months follow-up.  The sample size, 
however, was small and the absence of a brief treatment comparison condition 
without a computer pre-empts any conclusion about the computer’s effectiveness over 
and above that attributable to brief therapist contact alone.  The present study 
therefore was designed to address these shortcomings by employing a development of 
the computerized CBT package of Newman, et al. (1997). 
In order to assess the generalizability of the approach it was decided to conduct 
the study as an international multi-center trial, at the University of Queensland, 
Australia, and through Fife Healthcare, (now called Fife Primary Care NHS Trust) 
Scotland. The inclusion criteria permitted a wider range of patients to be included in 
the study than occurs in efficacy trials. Thus the aim was to frame the trial as an 
effectiveness study.  
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Method 
Participants 
In Scotland patients were recruited via referrals from general practitioners to the 
Adult Clinical Psychology Service in Fife and were seen for all treatment sessions in 
local outpatient clinics, health centers or surgeries. In Australia patients were recruited 
via referrals from general practitioners and through the media, and were seen for all 
treatments in the Psychology Clinic at the University of Queensland. Diagnostic status 
was confirmed using the Structured Clinical Interview for DSM - IV Axis I Disorders 
(SCID - I, First, Spitzer, Gibbon & Williams, 1997.) Ethical approval was obtained 
through the relevant Ethics Committees. Patients entered the study if they provided 
written informed consent and conformed to the following entry requirements: DSM-
IV (American Psychiatric Association, 1994) Panic Disorder with or without 
Agoraphobia; current episode duration of at least three months; age 18 to 60 years 
inclusive; consider panic their main problem; willing to accept random allocation, 
including the waiting list condition; no depressive disorder severe enough to require 
urgent treatment; no cognitive-behavior therapy for the current episode; no evidence 
of organic mental disorder, schizophrenia, alcohol or drug dependence, cardiovascular 
disease, asthma, epilepsy, pregnancy or intention to become pregnant during the 
course of the study.  Concurrent Axis II personality disorder was not a reason for 
exclusion unless the personality disorder was clearly the primary problem. All 
patients taking medication at the time of entry must have been on a stable dose for 
three months and must have been willing and able to remain on a stable regime for 
three months during the course of treatment. 
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Patients who failed to receive at least three sessions of their respective course of 
treatment or provide adequate pre-treatment and end-point data were defined as 
dropouts. Patients who dropped out were replaced.   
Treatments 
Therapy was conducted by licensed psychologists with extensive experience of 
CBT. Each therapist was assigned patients randomly which resulted in each therapist 
treating approximately equal proportions of patients in each of the three treatment 
conditions. In the brief treatment conditions the time allocated to cover content was 
reduced from 12 to 6 one-hour sessions.. This was equivalent to the time allocation 
for brief CBT for panic disorder evaluated by Clark et al (1999), and to the time 
allocation in our pilot outcome study (Newman et al, 1997.) It was determined 
through the pilot study that six hours was sufficient time to deliver the content of the 
standard protocol. Based on client feedback, it was decided that, instead of being 
delivered over four sessions (six hours contact) (Newman et al, 1997), the therapy 
would be over six sessions, each of one hour. The manuals provided specific detail of 
content to be covered within each session including session agendas, information to 
be presented, homework exercises, and specific therapeutic procedures (e.g. 
interoceptive exposure, relapse prevention.) The CBT approach was based on Panic 
Control Treatment (Barlow et al, 1989) that incorporated the cognitive and behavioral 
theories of panic (e.g. Barlow et al, 1989; Clark, 1986) and standard cognitive and 
behavioral techniques. The protocol was adapted from Panic Control Treatment 
protocols but also included a graded exposure component. Graded exposure was 
introduced after the second session. Patients were encouraged to engage in self-
directed exposure as part of homework, and progress was monitored throughout 
treatment.  
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All sessions for all treatment conditions were tape-recorded and a random 
selection (20%) of tapes were exchanged between sites and rated by JK and MD to 
ensure adherence to treatment protocols and therapeutic competence. There were no 
significant effects for Site, Treatment, or Site X Treatment on protocol adherence or 
therapeutic adequacy. Therapists also completed a separate checklist for each therapy 
session to evaluate adherence to the protocol. The correlation between therapist-rated 
and externally rated protocol adherence was 0.92 (p<.001). No significant differences 
were found on therapist-rated treatment protocol compliance across Site or Treatment, 
or for Site X Treatment. Overall, there was 97.1 % protocol adherence. 
CBT12, or standard treatment, involved 12 weekly 1-hour individual sessions 
with the therapist. Average number of sessions completed was 10.5. The six-week 
treatment protocols, CBT6 and CBT6-CA constituted a condensed version of the 
standard CBT 12 regime including individual sessions with the therapist, the same 
content and the same supplementary handouts. Total therapist contact time, however, 
for the brief treatments (CBT6 and CBT6-CA) was 6 hours (i.e. six weekly one hour 
contacts). This was equal to the contact time of the brief treatment condition in 
Newman et al (1997). On average patients completed 5.9 therapy sessions in CBT6-
CA and 5.9 sessions in CBT6. In the CBT6-CA condition, patients continued to carry 
the palmtop computer for the remaining 6 weeks, after which it was returned.   
Computer 
The palmtop computer used in the CBT6-CA was the Hewlett Packard 200LX, 
which weighs about 300 g and when folded measures 16 x 2.5 x 8.5 cm.  It unfolds 
into two sections:  a QWERTY keyboard with function keys, and a screen (16 lines by 
40 characters).  The computer was programmed to signal the subject five times daily - 
at 800am; 1100am; 4.00pm; 7.00pm and 9.00pm to prompt the practice of the therapy 
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components. The computer program included a self-statement module, a breathing 
control module, and a new exposure module incorporating both situational exposure 
and interoceptive exposure. The exposure included goal setting and specification of 
exposure tasks. In the case of interoceptive exposure specific tasks, such as 
hyperventilation, were presented in relation to concern about particular salient somatic 
symptoms, such as difficulty breathing. 
Measures 
The primary measures comprised a comprehensive battery of panic and anxiety 
measures, comparable to that employed by Clark and colleagues (Clark, et al, 1994; 
1999).  Secondary outcome measures assessed disability and quality of life.  These 
were completed pre-treatment, post-treatment, and at 6-months follow-up.  Frequency 
of panic attacks over the last 2 weeks was assessed using a 5-point (0-4) scale.   In 
addition, panic-related distress/disability was rated on a 9-point scale, where 0 
represented ‘not at all disturbing and/or disabling’, 2 ‘slightly’, 4 ‘definitely’, 6 
‘markedly’ and 8 ‘very disturbing/disabling’.  Phobic avoidance was assessed by the 
Fear Questionnaire (Marks & Mathews, 1979.)  Patients also completed the Mobility 
Inventory for Agoraphobia (Chambless, Caputo, Jasin, Gracely & Williams, 1985) 
which yields an average score for situational avoidance, both when accompanied and 
alone;  the Body Sensations Questionnaire (BSQ;  Chambless, Caputo, Bright & 
Gallagher, 1984) which assesses degree of anxiety and selective attention to physical 
symptomatology and sensations; and the Agoraphobic Cognitions Questionnaire 
(ACQ;  Chambless et al, 1984) which was used as an additional measure of panic-
related cognition. General anxiety was assessed using the State-Trait Anxiety 
Inventory-Form X Trait Scale  (STAI-T; Spielberger, Gorsuch & Lushene, 1970.)   
Depression was assessed by the Beck Depression Inventory (BDI; Beck, Steer & 
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Garbin, 1988). The Medical Outcomes Survey Short Form 36 (SF-36;  Ware & 
Sherbourne, 1992) was used as a general measure of Quality of Life and broad health 
status. Two standardized Component scores, Mental and Physical, are derived from 
the SF-36.  
At the first treatment session patients not in the wait-list condition completed a 
four-item scale of treatment outcome expectancy. Items were rated on a 5-point scale 
from ‘not at all’ (1) to ‘extremely’ (5) and scores were summed to give a total score. 
Patients in the CBT6-CA condition also completed a question on satisfaction with the 
computer using the same five-point scale. 
Statistical Analysis 
To ensure initial equivalence among groups across sites, pre-treatment/wait 
scores for the three treatment groups and waitlist were compared by separate two-way 
analyses of variance (ANOVAs) for each measure.  For the outcome analyses between 
site and group differences pre- to post-treatment and pre- to follow-up were examined 
by means of repeated-measures analyses of variance (ANOVAs). Planned 
comparisons were used to identify significant between-group differences.  These were 
Waitlist vs. active treatments, CBT12 vs. CBT6CA, CBT12 vs. CBT6 and CBT6CA 
vs. CBT6. These were chosen to test the study hypotheses. The main analysis was 
based on a single unweighted composite panic-anxiety measure (Clark et al 1994; 
Connors, Epstein, March, Angold, Wells, Klaric et al, 2001). Additional analyses 
were conducted on individual panic/anxiety measures if significant between-group 
differences were found. The composite score was calculated by the procedure 
recommended by Connors, Epstein, March, Angold, Wells, Klaric et al, (2001).  
Effect size is calculated using the formula ES = (Xcomp - Xref) / SDref  (Gould et al, 
1995), where Xcomp is the mean of the comparison group, Xref  is the mean of the 
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reference (or control) group, and SDref  is the standard deviation of the reference 
group. To determine clinical significance the reliable change index (RCI) was 
calculated for each variable using norms and test-retest reliability estimates, and then 
a cut-off score of 1.96 standard deviation units was applied. (Newman et al, 1997).  
The outcome was defined as clinically significant when the RCI exceeded the cut-off 
score so that the mean was closer to a functional population.   Panic-free status and 
Clinically Significant Change status were analyzed using binary logistic regression 
analyses. A coding system was used in which one category was designated a reference 
category (Tabachnick & Fidell 1996). Sample size was based on a mean effect size for 
CBT for panic disorder of 0.68 (Gould, et al, 1995), and calculated based on 80% 
power, two-tailed α = 0.05, and a drop-out rate of 10-15%.  
An intention-to-treat analysis was also conducted in which all cases with 
available pre-treatment data were carried forward. Since most of the pre-treatment 
dropouts did not have complete data available for calculation of the composite, it was 
decided to use panic-free status as the outcome variable as data were available for all 
subjects at pre-treatment. The intention-to-treat analysis was limited to 3-month post-
treatment since it was judged that extrapolation of pre-treatment data to the 6-month 
follow-up was untenable. 
Results 
In total 186 patients met the above entry criteria and were offered and accepted a 
place in the study. Of these 163 patients (87.6%)  commenced treatment (waitlist n = 
41, CBT6 n = 39, CBT6-CA n = 41, CBT12 n = 42.)  Twenty-three patients (14.1%) 
failed to receive at least three sessions of their respective course of treatment or 
provide adequate data and were classified as drop-outs.  A further 13.1% (n = 14/107) 
of completers in the active treatment conditions were lost to follow-up. This left 93 
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patients who had adequate 9-month data to allow for follow-up analysis.. No 
differences were found between dropouts and completers on the main outcome 
measures or duration of disorder. 
The mean age of the sample was 36.8 years (SD = 10.00), with 75.5% female. 
The majority of patients had a diagnosis of Panic Disorder with Agoraphobia (76.1%.) 
Patients in Scotland had a significantly greater mean duration current episode 
compared to the Australian patients, 40.2 months compared to 114.9 months, F 
(1,163) = 34.11, p<.001. Overall 52 (33.1%) patients had completed at least some 
post-secondary education, and there was also a significant difference between sites on 
education level with 47.4% of the Australian patients having completed some post-
secondary education compared to 23% of the Scottish patients, χ2 (2, N = 163) = 
16.67,  p<.001. Significantly more of the Australian patients (46.4%) were prescribed 
concurrent benzodiazepines compared to Scottish patients, 14.1%, χ 2(1, N = 163) = 
21.01,  p<.001.  
Main Outcomes 
 Table 1 shows the mean composite and individual measure scores before 
treatment/wait, at post-treatment/wait and at 6 months follow-up.  The results of a 
series of two-way (Site X Treatment) ANOVAs to compare pre-treatment/waiting list 
scores for the composite and all individual outcome measures for treatment 
commencers revealed significant differences for Site on the two Mobility Inventory 
subscales, Alone F (1, 155) = 4.40,  p<.05, Australia M = 2.91 (SD = 1.07) vs. 
Scotland M = 3.28 (SD = 1.14); Accompanied F ( 1, 155) = 4.60, p<.05, Australia M 
= 2.20 (SD = 0.93) vs. Scotland M = 2.53 (SD = 0.98). No other differences were 
found. 
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In order to examine pre- to post-treatment outcome a three-way repeated-
measures ANOVA with Site (Australia, Scotland) X Treatment (Waitlist, CBT6, 
CBT6-CA, CBT12) X Time (Pre-, Post-) as independent variables was conducted on 
composite scores.  No significant Site X Treatment X Time or Site X Time interaction 
was found. The Treatment X Time interaction was highly significant (Table 1).  
Planned comparisons on the pre- to post-treatment composite scores revealed that all 
treatment conditions were significantly better than wait-list, that CBT12 was 
significantly better than CBT6, but that CBT6-CA did not differ significantly from 
either CBT12 or CBT6. Effect sizes (ES) between the treatment conditions and the 
wait-list calculated on the post-treatment composite scores (Gould et al, 1995.) The 
treatments were all more effective than the wait-list, with large effect sizes overall, 
CBT6 ES = 1.51, CBT6CA ES = 1.96, CBT12 ES = 2.16. However, a significant 
difference between treatment conditions in effect size was found only for CBT12 and 
CBT6 at post- treatment ES = 0.82,  p<.01. 
For the individual measures, the only significant Site X Treatment X Time effect 
was for STAI-T, F(3, 140) = 4.28, p<.005. There was a significantly greater reduction 
in trait anxiety in the CBT6-CA condition in Australia than in Scotland, t(33) = 2.29, 
p<.05. Planned comparisons between treatment conditions on all individual measures 
comprising the composite score showed all treatments to be significantly superior to 
the waiting list (Table 1). While differences between CBT12 and CBT6 conditions 
were not uniformly significant, there was nevertheless a consistent trend favoring 
CBT12 over the CBT6 condition, with CBT6-CA occupying an intermediate position 
on each outcome measure.   The same pattern of results was found for  Beck 
Depression Inventory, F(3, 132) = 10.08,  p<.001, SF-36 Mental Component F(3, 
118) = 6.71,  p<.001, and SF-36 Physical Component  F(3, 118) = 4.27,  p<.01.  
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Clinically Significant Change and Panic-free Status 
 The main outcome variables were also analyzed using clinically significant 
change. Table 2 presents the results of those analyses. No significant Site or 
Treatment X Site effects were found on any outcome variable. Significant Treatment 
effects were found on all outcome variables except the FQ-Ag and FQ-Soc. These 
effects, however, were only found for CBT12 and CBT6CA with reference to the 
waiting list condition, with no significant difference between CBT6 and waiting list. 
At post treatment, using a logistic regression analysis,  there was a significant 
prediction of panic free status.  While neither Site nor Site X Treatment significantly 
predicted high panic free status, Treatment was a significant predictor at all levels 
with reference to the waiting list condition,  CBT12 OR = 32.22 (7.92 - 131.03), 
CBT6-CA OR = 21.82 (5.46 - 87.14), and CBT6 OR = 8.89 (2.27 - 34.79). CBT12 
and CBT6-CA produced similar outcomes (Figure 1).  In contrast, fewer patients in 
the CBT6 treatment reached panic-free status at the end of treatment. Using CBT12 
as the reference category CBT6-CA did not differ from CBT12, OR = 0.68 (0.24 - 
1.90), but CBT6 was significantly worse than CBT12, OR = 0.28 (0.10 - 0.76.) 
Similar results were found with an intention-to-treat analysis. 
Follow-up 
To assess whether treatment effects were sustained over the course of the 
follow-up period, a three-way repeated-measures ANOVA with Site (Australia, 
Scotland) X Treatment (CBT6, CBT6-CA, CBT12) X Time (Pre-, Follow-up) as 
independent variables was conducted on the composite scores. The only significant 
effect was for Time, F(1, 87) = 255.55, p<.001,  indicating a significant improvement 
from pre-treatment to follow-up across all treatment conditions. ANOVA’s performed 
on variables that made up the composite found a main effect for Time in the direction 
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of improvement [Panic frequency F(1, 87) = 128.57,  p<.001; Panic severity F(1, 87) 
= 150.21,  p<.001; BSQ F(1, 87) = 150.99, p<.001; ACQ F(1, 87) = 125.32, p<.001; 
STAI-T F(1, 87) = 95.16, p<.001; MI-Al F(1, 87) = 84.37, p<.001; MI-Ac F(1, 87) = 
43.40,  p<.001; FQ-Ag F(1, 87) = 96.23, p<.001; FQ-Soc F(1, 87) = 71.54, p<.001; 
FQ-BI F(1, 87) = 46.70, p<.001.] The only significant Time X Treatment interaction 
was for FQ-BI, F(2, 87) = 4.18, p<.05) where there was greater improvement in 
CBT6 compared to CBT6-CA. In summary, treatment gains were sustained over the 
follow-up period, and there was little evidence of differential improvement between 
treatment conditions.  
No significant differences were found for outcome expectancy. Positive 
treatment outcome expectancy predicted improvement on the composite at post-
treatment (r = .29, p<.001), but not at follow-up. Satisfaction with the computer 
significantly predicted improvement on the composite pre- to post-treatment (r = 0.46, 
p<.05) but not post-treatment to follow-up. Concurrent use of anxiolytic or 
antidepressant medication did not predict improvement on the composite pre- to post-
treatment or maintenance post-treatment to follow-up.  When the primary analysis of 
the composite score was repeated including only those patients who were medication 
free, this yielded the same pattern of results as for the whole sample. 
Discussion 
 This is the first randomized, multi-site international trial involving CBT.  It is also 
significant given the relatively large number of patients involved in the study, the use 
of sites from two different countries, and the liberal inclusion criterion. The results of 
the primary analysis are complex.  While they indicate that the most favorable 
outcome at post-treatment is obtained from a standard duration treatment,, a brief 
version, when augmented with a computer, is not significantly different in 
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effectiveness. Furthermore, a brief version without computer augmentation performs 
significantly worse than the standard duration treatment at post-treatment, but is no 
different from brief, computer-augmented treatment.  Thus, there is some evidence, 
albeit mixed, that the brief computer-augmented treatment does impact positively on 
post-treatment outcome since, on all variables, it is associated with better outcomes 
than the brief condition alone. At six-months follow-up the picture changes with CBT  
delivered in the standard or in a shorter version with or without computer, resulting in 
similar level of significant improvement in all patients.  The more conservative 
intention-to-treat and clinically significant change analyses mirror this result.  Thus 
the impact of length of treatment fails to carry through to follow-up, where all 
treatments cannot be distinguished statistically. This replicates, with a greatly 
increased sample size, the findings of Newman, et al (1997).  However, more power 
may have helped to detect differences between the conditions.  While not statistically 
significant, apparent improvement from post-treatment to follow-up in the brief 
therapy condition may be explained, in part, by differential attrition. For example 
panic-free status in post-treatment to follow-up drop-outs was 33.3% (2/6) in the brief 
therapy condition compared to 80% (4/5) in the brief computer-aided therapy 
condition. Also, dropouts in the brief therapy condition had a more chronic history 
(111.8 mo.) than in the brief computer-aided therapy condition (46.4 mo.).  
The level of effectiveness of the standard therapy and brief therapy is consistent 
with that found in the literature (Gould, et al, 1995).  The effect sizes on the 
composite score were comparable to those found by Clark, et al (1994). While the 
difference in the effect size for the composite score at post-treatment between brief 
and standard therapy was significant, the effect size compared to wait-list for brief 
therapy was still large. If the standard therapy were augmented with the computer, it 
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might be possible to produce a more powerful treatment than the standard treatment. 
Future research could explore this possible development. 
The superiority of the full implementation of CBT over the brief treatment at 
post-treatment contrasts with Clark, et al (1999) who found no differences between 
brief and full implementation of CBT for panic disorder.   However, in their brief 
therapy these authors conducted five brief cognitive therapy sessions (total therapist 
contact time 6.5 hours) over a three-month period, whereas in the current study, six 
sessions (6 hours) were conducted across 6 weeks. Further Clark et al. included self-
study modules that were comparable to bibliotherapy. Differences in sample 
characteristics may have been important since our patients had higher levels of 
depressive symptoms and a more chronic presentation than patients in the Clark et al. 
study. One limitation of the present study was the use of self-report outcomes. This 
meant that evaluation of diagnosis was not possible at post-treatment or follow-up.  
Consistent with previous work (Newman et al, 1996; 1997) the computer was 
well accepted. This is particularly impressive given that 26% of the Scottish and 36% 
of the Australian sample using the computer had a post-secondary education.. On 
average each computer received 84 weeks of constant use. This has implications for 
the cost of the use of the computer as an adjunct to treatment. Since one reason for 
using the computer in this study was to improve treatment efficiency and reduce cost, 
it is worthwhile examining relative costs of the treatments. Based on an average fee 
for service of $100 per therapist contact hour, palmtop computer hardware costs, 
software costs and base station costs (distributed over seven patients), the relative 
costs are $1200 for the standard therapy, $600 for the brief therapy, and $680 for the 
computer-assisted brief therapy. This is the first international multi-site study and by 
far the largest study  to examine the effectiveness of CBT for panic disorder (although 
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Marks, Swinson, Basoglu, Kuch, Noshirvani, O’Sullivan, et al.,(1993) conducted a 
trial of exposure versus alprazolam for panic disorder in Canada and the United 
Kingdom.) Matched studies of CBT in different cultures with different health care 
systems are rare and much may be learned from these detailed comparisons. Important 
differences were found in concurrent medication usage, and chronicity of the disorder. 
In the United Kingdom there has been a significant reduction in the frequency of 
prescription of benzodiazepines with rates in general practice of approximately 4% 
(Holden, Hughes, and Tree, 1994). In contrast in Australia the rate of prescription in 
primary care for anxiety is about 50% (Mant, Mattick, de Burgh, Donnelly, & Hall, 
1995.) Greater chronicity in the Australian patients may reflect the reduced 
accessibility to health care professionals who can deliver effective treatment for 
anxiety disorders in the United Kingdom than in Australia. In contrast to the United 
Kingdom where clinical psychology services are provided as part of the National 
Health Service via referral from primary care, no such scheme exists in Australia. 
This means that patients with anxiety disorders are more likely to receive CBT earlier 
in the course of the disorder than in Australia. In spite of these differences, it can be 
concluded from the similarity of the results in the two countries, that CBT for panic 
disorder is equally effective in both, and hence that treatment effectiveness is robust 
to cultural differences. Perhaps more relevant to the use of computers was the 
educational differences found between the Scottish and the Australian samples. 
However, adding hand held computers to brief CBT did not appear to be associated 
with any differential attrition, treatment outcomes or satisfaction with treatment.  
Conclusion 
This study, conducted at relatively low cost but involving an international group 
of  investigators and a large number of patients demonstrates the feasibility of 
 18
international collaborative efforts examining psychological therapies.  Although the 
investigators met yearly, the meetings were brief and much of the communication 
occurred via the Internet.    The availability of standardized measures, diagnostic 
criteria and standard protocols and procedures were critical in this effort.   Multi-site 
studies conducted in this way allow effectiveness trials to be conducted more rapidly 
and less expensively; and have the added benefit of expanding the generalizability and 
importance of the findings.  The use of computers as an innovative adjunctive therapy 
tool received some support and merits further investigation. 
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Table 1 presents means and standard deviations (in brackets) for the analysis of 
composite and outcome variables for each time point.  
 
Variable Time A.W/L B.CBT6 C.CBT6- 
CA 
D.CBT12 Treatment X Time 
and planned 
comparisons 
Pre-
treatment 
0.08 
(0.64) 
0.02 
(0.65) 
-0.11 
 (0.59) 
-0.08 
(0.57) 
 
Post-
treatment 
0.04 
(0.70) 
-1.02  
(0.77) 
-1.33   
 (0.69) 
-1.47  
(0.55) 
F(3,132) = 34.05*** 
A>B,C,D; B>D 
Composite 
6 month 
follow-up 
N/A -1.21 
(0.76) 
-1.21  
(0.76) 
-1.52 
(0.70) 
 
Pre-
treatment 
2.55 
(0.87) 
2.35 
(1.07) 
2.49 
(0.70) 
2.50  
(1.25) 
 
Post-
treatment 
2.55 
(1.20) 
0.91  
(1.03) 
0.66  
(1.14) 
0.35  
(0.68) 
F(3,132) = 18.06*** 
A>B,C,D; B>D 
Panic 
frequency 
(client rated)  
(0-4) 
6-month 
follow-up 
N/A 0.72 
(1.14) 
0.77 
(1.12) 
0.69 
(1.15) 
 
Pre-
treatment 
5.09 
(1.53) 
5.07 
(1.86) 
4.77 
(1.61) 
4.93 
(1.62) 
 
 
Post-
treatment 
4.83 
(1.94) 
2.24  
(1.79) 
2.00  
(1.95) 
1.68  
(1.79) 
F(3,132) = 12.00*** 
A>B,C,D 
Panic Severity 
(client rated)  
(0-8) 
6-month 
follow-up 
N/A 1.75 
(2.51) 
1.95 
(2.13) 
1.37 
(1.78) 
 
Pre-
treatment 
3.28 
(0.79) 
3.32 
(0.61) 
3.23 
(0.86) 
3.17 
(0.89) 
 
 
Post-
treatment 
2.99 
(0.92) 
2.22  
(0.78) 
1.85   
(0.72) 
1.67  
(0.68) 
F(3,132) = 11.94*** 
A>B,C,D;B>D;C>D 
Body 
Sensations 
Questionnaire 
(BSQ) 
6-month 
follow-up 
N/A 2.21 
(0.77) 
2.08 
(0.72) 
1.64 
(0.69) 
 
 
Pre-
treatment 
2.71 
(0.67) 
2.81 
(0.76) 
2.70 
(0.82) 
2.55 
(0.76) 
 
 
Post-
treatment 
2.59 
(0.82) 
1.92  
(0.79) 
1.68  
(0.62) 
1.56  
(0.46) 
F(3,132) = 10.31*** 
A>B,C,D; B>D 
Agoraphobic 
Cognitions 
Questionnaire 
(ACQ) 
6-month 
follow-up 
N/A 1.80 
(0.72) 
1.76 
(0.60) 
1.49 
(0.56) 
 
Pre-
treatment 
55.88 
(9.70) 
58.09 
(10.60) 
55.55 
(9.04) 
55.92 
(11.41) 
 
 
Post-
treatment 
54.90  
(11.44) 
47.86   
(12.31) 
42.22  
(10.84) 
41.10  
(13.14) 
F(3,132) = 13.16*** 
A>B,C,D; B>D 
State-Trait 
Anxiety 
Inventory-
Trait  
(STAI-T) 6-month 
follow-up 
N/A 45.54 
(11.74) 
44.30 
(10.79) 
38.71 
(14.78) 
 
Pre-
treatment 
3.10 
(1.12) 
3.01 
(1.14) 
2.95 
(1.18) 
3.16 
(1.04) 
 
 
Post-
treatment 
3.21 
(1.06) 
2.41  
(1.16) 
2.03  
(1.04) 
1.97  
(0.74) 
F(3,132) = 17.10*** 
A>B,C,D 
Mobility 
Inventory-
Alone (MI-Al) 
6-month 
follow-up 
N/A 2.26 
(1.11) 
2.13 
(1.03) 
1.89 
(0.90) 
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Pre-
treatment 
2.48 
(1.00) 
2.32 
(0.99) 
2.22 
(1.00) 
2.34 
(0.93) 
 
 
Post-
treatment 
2.61 
(0.99) 
1.80  
(0.85) 
1.59  
(0.80) 
1.55  
(0.51) 
F(3,132) = 9.79*** 
A>B,C,D 
Mobility 
Inventory-
Accompanied 
(MI-Ac) 
6-month 
follow-up 
N/A 1.79 
(0.87) 
1.71 
(0.90) 
1.50 
(0.53) 
 
 
Pre-
treatment 
20.57 
(12.15) 
19.18 
(9.87) 
16.80 
(11.39) 
16.84 
(10.73) 
 
 
Post-
treatment 
19.92 
(11.09) 
11.40  
(9.55) 
8.02  
(8.88) 
7.05  
(7.91) 
F(3,132) = 8.33*** 
A>B,C,D; B>D 
Fear 
Questionnaire- 
Agoraphobia 
(FQ-Ag) 
6-month 
follow-up 
N/A 8.79 
(7.09) 
8.80 
(9.55) 
6.46 
(8.47) 
 
 
Pre-
treatment 
19.53 
(8.92) 
16.62 
(9.05) 
16.69 
(9.18) 
15.89 
(8.37) 
 
 
Post-
treatment 
19.78 
(8.69) 
12.53  
(8.27) 
9.80  
(7.11) 
9.03  
(7.96) 
F(3,132) = 9.14*** 
A>B,C,D 
Fear 
Questionnaire- 
Social Phobia 
(FQ-Soc) 
6-month 
follow-up 
N/A 10.75 
(7.74) 
10.97 
(6.72) 
6.97 
(7.27) 
 
 
Pre-
treatment 
16.40 
(9.33) 
17.18 
(8.89) 
12.66 
(9.08) 
13.62 
(8.15) 
 
 
Post-
treatment 
17.38  
(9.51) 
12.62   
(9.13) 
8.96  
(6.83) 
9.30  
(7.00) 
F(3,132) = 6.50*** 
A>B,C,D 
Fear 
Questionnaire- 
Blood/injury  
(FQ-BI) 
6-month 
follow-up 
N/A 9.36 
(6.38) 
10.47 
(8.45) 
8.31 
(7.51) 
 
***p<.001 
Note: Only significant planned comparisons are reported.
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Table 2 Percentage meeting conjoint criteria for clinically significant change* 
 
 
 
Variable Time W/L CBT6 CBT6CA CBT12 χ2(7) 
Post-
treatment§ 
6.1 38.2 45.7§ 51.4§ 28.42, p<.001 Body 
Sensations 
Questionnaire 6-month 
follow-up 
 
N/A 32.1 30.0 55.9  
Post-
treatment§ 
20.6 50.0 64.7§ 55.3§ 20.54, p=.005 Agoraphobic 
Cognitions 
Questionnaire 6-month 
follow-up 
N/A 60.7 48.3 54.3  
Post-
treatment§ 
5.9 48.5 60.0§ 60.5§ 43.87, p<.001 State-Trait 
Anxiety 
Inventory-Trait 6-month 
follow-up 
N/A 48.1 46.7 60.0  
Post-
treatment§ 
2.9 26.5 54.5§ 60.5§ 39.85, p<.001 Mobility 
Inventory-
Alone 6-month 
follow-up 
 
N/A 39.3 44.8 60.0  
Post-
treatment§ 
2.9 32.4 36.4§ 47.4§ 25.57, p=.001 Mobility 
Inventory-
Accompanied 6-month 
follow-up 
N/A 39.3 41.4 48.6  
Post-
treatment§ 
14.7 38.2 37.1 43.2 10.28, p=.173 Fear 
Questionnaire- 
Agoraphobia 6-month 
follow-up 
N/A 39.3 36.7 47.1  
Post-
treatment§ 
8.8 20.6 28.6 32.4 6.92, p=.44 Fear 
Questionnaire- 
Social Phobia 6-month 
follow-up 
N/A 27.9 30.0 47.1  
Post-
treatment§ 
8.8 44.1 42.9§ 45.9§ 19.66, p=.006 Fear 
Questionnaire- 
Blood/injury  6-month 
follow-up 
N/A 65.5 28.7 38.7  
 
 
*Conjoint criteria represents the percentage of individuals who reliably improved 
(reliable change index > 1.96) and whose mean placed them closer to the mean of the 
functional population than the mean of the dysfunctional population. 
§Differ significantly from W/L at p<.05 
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Figure Captions 
 
 
Figure 1 Top Panel: Percentage panic-free post-treatment and 6-month follow-up. 
Bottom Panel: Percentage panic-free at post-treatment using Intention-to-Treat 
analysis. 
 
 
 
 
